Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2004 | 1 |
2006 | 1 |
2008 | 1 |
2023 | 0 |
Search Results
3
results
Results by year
Page 1
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease.
J Pharmacol Exp Ther. 2008 Apr;325(1):77-88. doi: 10.1124/jpet.107.130443. Epub 2008 Jan 24.
J Pharmacol Exp Ther. 2008.
PMID: 18218832
Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease.
Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, Abraham WM, Boucher RC.
Hirsh AJ, et al. Among authors: zamurs a.
J Pharmacol Exp Ther. 2004 Dec;311(3):929-38. doi: 10.1124/jpet.104.071886. Epub 2004 Jul 23.
J Pharmacol Exp Ther. 2004.
PMID: 15273255
Item in Clipboard
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
Hirsh AJ, Molino BF, Zhang J, Astakhova N, Geiss WB, Sargent BJ, Swenson BD, Usyatinsky A, Wyle MJ, Boucher RC, Smith RT, Zamurs A, Johnson MR.
Hirsh AJ, et al. Among authors: zamurs a.
J Med Chem. 2006 Jul 13;49(14):4098-115. doi: 10.1021/jm051134w.
J Med Chem. 2006.
PMID: 16821771
Item in Clipboard
Cite
Cite